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Rabies is a zoonotic viral disease with a mortality by close to 100%. As there is not an efficacious treatment 
available, post-exposure vaccination is recommended for individuals in contact with the virus. On the other 
hand, the most common source of virus transmission is saliva of infected animals, mostly dogs, whereby mass 
vaccination of pets is the most cost-effective way to reduce human infections. In this context, availability of both 
human and veterinary vaccines is critical. 
 
In previous works1-2, our group developed immunogenic rabies VLPs, expressing the virus glycoprotein in 
HEK293 cells. We obtained a producer clone capable of growing in adherence (adhP2E5) and then adapted to 
suspension conditions (sP2E5). In this work, we analyzed the production of VLPs in both conditions, using two 
different platforms. 
 
On the one hand, adhP2E5 was cultured in 850 cm2 roller bottles (GBO) using medium with 5% FCS, that was 
exchanged every 48 h during the first 10 days and every 24 h during the last 5 days. RV-VLPs were 
continuously produced and the harvest obtained (2.5 L per bottle) was analyzed by sandwich ELISA, using the 
6th International Standard for rabies vaccine that quantify the glycoprotein content (NIBSC), presenting a value 
of 19 IU.ml-1 in average. On the other hand, we cultured sP2E5 in a 5 L bioreactor during 15 days, using 
EX-CELL293 SFM (SAFC). The culture reached densities of 2x107 cel.ml-1 and VLPs were continuously 
secreted to the supernatant. The obtained harvest (28.5 L) presented a glycoprotein content of 28 IU.ml-1, a 
results that is comparable with the previous one taking into account the number of cells presents in both 
conditions. 
 
These results showed that our clone could be cultured in both platforms depending on the objectives and 
characteristics of the desired product. For the production of the rabies veterinary vaccine, RV-VLPs can be 
produced in adherent conditions using medium supplemented with FCS and, for human vaccine production, RV-
VLPs can be produced in bioreactors using SFM.  
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